| Adebrelimab Combined With Albumin Paclitaxel for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Anti-PD-1 monoclonal antibody + LCB84 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| APG-157 for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Axelopran + pembrolizumab for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD6750 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD6750 + Rilvegostomig for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Balstilimab + evofosfamide + zalifrelimab for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Becotatug for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Becotatug Vedotin for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BMX-001 for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + NAB-PACLITAXEL + Cetuximab + CISPLATIN for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + Paclitaxel for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Combination 5-azacytidine and nivolumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CP-383 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CR-002 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dalpicilib combined with cetuximab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Eliminating RT to the elective neck for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enlonstobart for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Evorpacept for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FAPi-46 GA-68 for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + Tersolisib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GCP intratumoral catheter for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-108 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hafnium oxide for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| High Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LCB84 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Loco-regional radiotherapy for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Low Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Medium Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| N17350 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Near-infrared fluorescence imaging + Indocyanine Green for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nimotuzumab, Benmelstobart for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + ipilimumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + relatlimab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab and Ipilimumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Petosemtamab for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiotherapy + CISPLATIN for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rimegepant for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab tirumotecan for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SI-B003 + Izalontamab for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sigvotatug Vedotin for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Spartalizumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Stereotactic Body Radiation Therapy (5 days) + Surgical Resection + PEMBROLIZUMAB for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6002 for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6002 + Becotatug + Enlonstobart for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6002 + Enlonstobart for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6010 injection + Enlonstobart for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6010 injection + PEMBROLIZUMAB for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tersolisib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tirellizumab combined with carboplatin and albumin-paclitaxel neoadjuvant therapy+surgery for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| VLS-1488 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 100 mg Tablet for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 Tablet and Pembrolizumab (200 mg) for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zanzalintinib for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|